Cadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Cadrenal Therapeutics

15/08/2026 24:05

Cadrenal Therapeutics Inc CVKD.OQ reported a quarterly adjusted loss of $1.14​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.87.  The mean expectation of three analysts for the quarter was for a loss of $1.42 per share. Wall Street expected results to range from $-1.95 to -95 cents per share.
Reported revenue was zero​; analysts expected zero. 
Cadrenal Therapeutics Inc's reported EPS for the quarter was a loss of $1.14​.
The company reported a quarterly loss of $3.32 million.
Cadrenal Therapeutics Inc shares had fallen by 44.3% this quarter and lost 72.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 8.2% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $13.00, about 85.6% above its last closing price of $1.87
This summary was machine generated from LSEG data August 14 at 11:05 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.42
-1.14
Beat
Mar. 31 2026 
-1.62
-1.04
Beat
Dec. 31 2025 
-1.16
-1.43
Missed
Sep. 30 2025 
-1.53
-1.31
Beat